Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (211-220 of 265) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter studyMatthew P Goetz, Matthew R Callstrom, J William Charboneau, et al.
Breast Cancer Research : BCR|May 21, 2020
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancerSwaathi Jayaraman, Xiaonan Hou, Mary J Kuffel, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2026
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal womenJinghan Cui, Susan E Hankinson, Alvin M Matsumoto, et al.
NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.
NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.
Pageof 27

Showing results (211-220 of 265) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2004
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter studyMatthew P Goetz, Matthew R Callstrom, J William Charboneau, et al.
Breast Cancer Research : BCR|May 21, 2020
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancerSwaathi Jayaraman, Xiaonan Hou, Mary J Kuffel, et al.
Molecular Cancer Therapeutics|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.
Oncotarget|March 4, 2021
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumorsNaoko Takebe, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Breast Cancer Research : BCR|June 10, 2024
Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancerRoberto A Leon-Ferre, Kaitlyn R Whitaker, Vera J Suman, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2026
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal womenJinghan Cui, Susan E Hankinson, Alvin M Matsumoto, et al.
NEJM Evidence|July 23, 2024
Clinical and Genomic Risk for Late Breast Cancer Recurrence and SurvivalJoseph A Sparano, Michael Crager, Robert J Gray, et al.
NPJ Breast Cancer|October 24, 2025
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trialAndrea E Wahner Hendrickson, Karen S Flatten, Taylor M Weiskittel, et al.
Pageof 27